FIELD: medicine. SUBSTANCE: object of this invention is production of desired product both on preparative and industrial scales. Essence of this process resides in adding human serum albumin culture to be taken in prescribed amount, changing medium, repeating cultivation, collecting, concentrating and purifying end product using method of ultrafiltration on membranes having pores from 80 to 100 nm in size. EFFECT: disclosed process permits scaling up production of desired product.
Title | Year | Author | Number |
---|---|---|---|
METHOD OF PHYLOVIRUS SUSPENSION CULTURING IN CELL CULTURE ON MICROCARRIERS | 1993 |
|
RU2076905C1 |
METHOD FOR PREPARING COMBINED BIVALENT, TISSUE-CULTURE, INACTIVATED, CONCENTRATED, PURIFIED VACCINE FOR PREVENTING HEMORRHAGIC FEVER AND RENAL SYNDROME | 2009 |
|
RU2445117C2 |
METHOD OF PREPARING VACCINE FOR TICK-BORNE ENCEPHALITIS CONTROL | 1993 |
|
RU2082432C1 |
METHOD OF PREPARING CULTURAL ANTIRABIES VACCINE | 1991 |
|
RU2032738C1 |
METHOD OF PREPARING VACCINE AGAINST HEPATITIS A | 1989 |
|
SU1672635A1 |
INACTIVATED VACCINE AGAINST VENEZUELAN EQUINE ENCEPHALOMYELITIS AND A METHOD OF ITS PREPARING | 1991 |
|
RU2035191C1 |
METHOD OF OBTAINING INACTIVATED VACCINE AGAINST COVID-19 AND VACCINE OBTAINED BY METHOD | 2023 |
|
RU2810740C1 |
WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
ANTIVIRAL PREPARATION AND METHOD OF PREPARING IMMUNOGLOBULIN FOR PROPHYLAXIS AND TREATMENT OF PATIENT WITH VIRAL DISEASES | 1999 |
|
RU2144379C1 |
PLASMID CARRYING VECTOR CONTAINING RUBELLA VIRUS CDNA (24S RNA) | 2000 |
|
RU2167938C1 |
Authors
Dates
1995-02-27—Published
1991-10-14—Filed